Drug Profile
Safotibant
Alternative Names: FOV 2304Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Fovea Pharmaceuticals
- Developer Fovea Pharmaceuticals; Sanofi
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Bradykinin B1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic macular oedema
Most Recent Events
- 30 Sep 2012 Discontinued - Phase-II for Diabetic macular oedema in Australia (Ophthalmic)
- 30 Sep 2012 Discontinued - Phase-II for Diabetic macular oedema in Belgium (Ophthalmic)
- 30 Sep 2012 Discontinued - Phase-II for Diabetic macular oedema in Czech Republic (Ophthalmic)